I kliniske studier ændrede lasofoxifen ikke metaboliseringen af dextromethorphan (CYP2D6- substrat) og chlorzoxazon (CYP2E1- substrat) eller farmakokinetikken af warfarin (CYP2C9- substrat), methylprednisolon (CYP3A4- substrat) eller digoxin (MDR1 P- glycoproteinsubstrat).
In clinical studies, lasofoxifene did not alter the metabolism of dextromethorphan (CYP2D6 substrate) and chlorzoxazone (CYP2E1 substrate) or the pharmacokinetics of warfarin (CYP2C9 substrate), methylprednisolone (CYP3A4 substrate) or digoxin (MDR1 P-glycoprotein substrate).